IL2 and neoplasm: Another NK engager platform, the tetraspecific ANKET (antibody-based NK cell engager therapeutics), contains an IL-2 variant that inhibits Treg stimulation, an antibody domain to a tumor antigen, an antibody domain to NKp46, and the Fc domain of IgG1 that binds CD16 (54).